Scinai Immunotherapeutics LTD Schedule 13G passive stakes

LCK JNK 1 LLC has reported beneficial ownership of 317,366 American Depository Shares, representing 6.33% of Scinai Immunotherapeutics Ltd.'s outstanding shares, as of April 27, 2026.

An amended Schedule 13G filing reveals updated beneficial ownership details for Scinai Immunotherapeutics Ltd. by Stone Daniel E. and RK Stone Miami, LLC.

Daniel E. Stone and RK Stone Miami, LLC collectively report a 16.61% beneficial ownership stake in Scinai Immunotherapeutics Ltd. ADSs.

Daniel E. Stone and RK Stone Miami, LLC reported increased beneficial ownership in Scinai Immunotherapeutics Ltd., holding 9.9% and 8.1% respectively.

YA II PN, Ltd. and its affiliates have disclosed a 9.9% beneficial ownership stake in Scinai Immunotherapeutics Ltd. through a Standby Equity Purchase Agreement, allowing the company to sell up to $10 million in ADSs.

LCK JNK 1 LLC has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Scinai Immunotherapeutics Ltd.'s American Depository Shares.

LCK JNK 1 LLC has filed a Schedule 13G, revealing a beneficial ownership of 9.5% of Scinai Immunotherapeutics Ltd.'s American Depositary Shares.

Daniel E. Stone has reported a 9.99% beneficial ownership stake in Scinai Immunotherapeutics Ltd., primarily through American Depositary Shares and pre-funded warrants.

Sabby Management, LLC, Sabby Volatility Warrant Master Fund Ltd, and Hal Mintz have jointly disclosed a 4.9% beneficial ownership stake in Scinai Immunotherapeutics Ltd. ADSs as of December 31, 2024.